KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Cost of Revenue: 2010-2025

Historic Cost of Revenue for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $85.9 million.

  • Emergent BioSolutions' Cost of Revenue fell 29.93% to $85.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.0 million, marking a year-over-year decrease of 144.88%. This contributed to the annual value of $276.0 million for FY2024, which is 9.69% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Cost of Revenue is $85.9 million, which was up 28.40% from $66.9 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Cost of Revenue high stood at $440.5 million for Q4 2021, and its period low was -$287.3 million during Q4 2024.
  • Its 3-year average for Cost of Revenue is $52.4 million, with a median of $88.5 million in 2025.
  • As far as peak fluctuations go, Emergent BioSolutions' Cost of Revenue plummeted by 146.33% in 2022, and later spiked by 106.72% in 2023.
  • Emergent BioSolutions' Cost of Revenue (Quarterly) stood at $440.5 million in 2021, then crashed by 146.33% to -$204.1 million in 2022, then declined by 5.19% to -$214.7 million in 2023, then plummeted by 33.81% to -$287.3 million in 2024, then decreased by 29.93% to $85.9 million in 2025.
  • Its Cost of Revenue was $85.9 million in Q3 2025, compared to $66.9 million in Q2 2025 and $88.5 million in Q1 2025.